Avadel Pharmaceuticals (AVDL) Stock Statistics & Valuation Metrics

Avadel Pharmaceuticals has a market cap or net worth of $1.57B. The enterprise value is $833.42M.

Avadel Pharmaceuticals has 97,097,640 shares outstanding. The number of shares has decreased by -2.65% in one year.

Avadel Pharmaceuticals’s return on equity (ROE) is -0.66 and return on invested capital (ROIC) is -35.79%.

The current PE Ratio of Avadel Pharmaceuticals is ―. Avadel Pharmaceuticals’s PEG ratio is ―.

In the last 12 months, Avadel Pharmaceuticals had revenue of 169.12M and earned -48.83M in profits. Earnings per share was -0.51.

In the last 12 months, operating cash flow was 5.45M and capital expenditures -181.00K, giving a free cash flow of 5.27M billion.

Avadel Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Avadel Pharmaceuticals upcoming earnings date is Nov 5, 2025, Before Open (Confirmed).

Avadel Pharmaceuticals as a current ratio of 2.75, with Debt / Equity ratio of 3.00%

In the past 12 months, Avadel Pharmaceuticals has paid -247.00K in taxes.

Avadel Pharmaceuticals EV to EBITDA ratio is -26.72, with an EV/FCF ratio of -20.26.

Avadel Pharmaceuticals has $81.55M in cash and marketable securities with $2.73M in debt, giving a net cash position of $78.82M billion.

Gross margin is 89.64%, with operating margin of -25.07%, and net profit margin of -28.87%.

The average price target for Avadel Pharmaceuticals is $21.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy